Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature-Reference-Cited by-同舟云学术

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature

Published:2009-05 Issue:2 Volume:64 Page:131-139
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Vilmar Adam,Sørensen Jens Benn

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference42 articles.

1. Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data analysis;Ardizzoni;J Natl Inst,2007

2. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy;Olaussen;N Engl J Med,2006

3. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer;Cobo;J Clin Oncol,2007

4. A gynecologic oncology group study of platinum–DNA adducts and excision repair cross complementation group 1 expression in optimal, stage III ovarian cancer treated with platinum-taxane chemotherapy;Darcy;Cancer Res,2007

5. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy;Smith;J Clin Oncol,2007

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene expression markers in peripheral blood and outcome in patients with platinum‐resistant ovarian cancer: A study of the European GANNET53 consortium;International Journal of Cancer;2024-04-27

2. XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer;Cells;2023-05-25

3. XPF-ERCC1 blocker improves the therapeutic efficacy of 5-FU- and oxaliplatin-based chemoradiotherapy in rectal cancer;2022-12-05

4. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance;Cancers;2022-09-20

5. Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial;ESMO Open;2021-10